Shares of HUTCHMED (00013) extended their rally, climbing more than 6% in early trading before settling with a 5.12% gain to HK$23, with turnover reaching HK$132 million.

The surge follows a Monday announcement from the company revealing that its subsidiary, Hutchison MediPharma (Shanghai) Ltd, has entered into an exclusive development and licensing agreement with a subsidiary of GSK. The deal grants the GSK entity worldwide rights, excluding mainland China, Hong Kong, Macau, and Taiwan, to develop and commercialize HMPL-A830.

Under the terms of the agreement, HUTCHMED will receive an upfront payment of $110 million and could be eligible for up to $1.295 billion in development, regulatory, and commercial milestone payments, alongside tiered royalties based on net sales.

Analysts at Huatai Securities highlight the company's robust proprietary research capabilities, noting its pipeline has consistently received validation through multiple licensing deals with multinational corporations. The strategy of independent discovery paired with global commercialization is clear: the blockbuster A830 licensing agreement underscores the worldwide value of its ATTC platform, with a global Phase I study expected to commence in the second half of 2026. Meanwhile, A251 and A580 are progressing smoothly through global Phase I trials, paving the way for additional molecules to enter clinical development. The company's track record includes prior BD agreements with AstraZeneca and Takeda, with overseas commercialization of those assets gradually gaining momentum. Fruquintinib's international sales continue to grow steadily, and the global Phase III trial of savolitinib in second-line NSCLC achieved positive PFS and OS results in August, positioning the drug for an anticipated FDA filing.